Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Alendronate affects calcium dynamics in cardiomyocytes in vitro.

Kemeny-Suss N, Kasneci A, Rivas D, Afilalo J, Komarova SV, Chalifour LE, Duque G.

Vascul Pharmacol. 2009 Nov-Dec;51(5-6):350-8. doi: 10.1016/j.vph.2009.09.002. Epub 2009 Oct 6.

PMID:
19815094
2.

Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.

Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS.

J Bone Miner Res. 2015 Apr;30(4):657-69. doi: 10.1002/jbmr.2401.

3.

The Effect of Alendronate Loaded Biphasic Calcium Phosphate Scaffolds on Bone Regeneration in a Rat Tibial Defect Model.

Park KW, Yun YP, Kim SE, Song HR.

Int J Mol Sci. 2015 Nov 6;16(11):26738-53. doi: 10.3390/ijms161125982.

4.

Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.

Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.

Nephrol Dial Transplant. 2009 May;24(5):1472-7. doi: 10.1093/ndt/gfn690. Epub 2008 Dec 15.

PMID:
19075192
5.
6.

The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva.

Yalçin F, Gurgan S, Gurgan T.

J Contemp Dent Pract. 2005 May 15;6(2):10-7.

PMID:
15915200
7.

Vascular action of bisphosphonates: In vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis.

Cutini PH, Rauschemberger MB, Sandoval MJ, Massheimer VL.

J Mol Cell Cardiol. 2016 Nov;100:83-92. doi: 10.1016/j.yjmcc.2016.08.017. Epub 2016 Oct 2.

PMID:
27705747
8.

Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.

Spadaro JA, Damron TA, Horton JA, Margulies BS, Murray GM, Clemente DA, Strauss JA.

J Orthop Res. 2006 May;24(5):936-44.

9.

Longer term effects of ouabain on the contractility of rat isolated cardiomyocytes and on the expression of Ca and Na regulating proteins.

Müller-Ehmsen J, Nickel J, Zobel C, Hirsch I, Bölck B, Brixius K, Schwinger RH.

Basic Res Cardiol. 2003 Mar;98(2):90-6.

PMID:
12607130
10.

Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.

Hassler N, Gamsjaeger S, Hofstetter B, Brozek W, Klaushofer K, Paschalis EP.

Osteoporos Int. 2015 Jan;26(1):339-52. doi: 10.1007/s00198-014-2929-5. Epub 2014 Oct 15.

PMID:
25315260
11.

Alendronate attenuates eosinophilic airway inflammation associated with suppression of Th2 cytokines, Th17 cytokines, and eotaxin-2.

Sasaki O, Imamura M, Yamazumi Y, Harada H, Matsumoto T, Okunishi K, Nakagome K, Tanaka R, Akiyama T, Yamamoto K, Dohi M.

J Immunol. 2013 Sep 15;191(6):2879-89. doi: 10.4049/jimmunol.1300460. Epub 2013 Aug 9.

12.

Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?

Kolios L, Hoerster AK, Sehmisch S, Malcherek MC, Rack T, Tezval M, Seidlova-Wuttke D, Wuttke W, Stuermer KM, Stuermer EK.

Calcif Tissue Int. 2010 Jan;86(1):23-32. doi: 10.1007/s00223-009-9318-7. Epub 2009 Dec 1.

13.

Fructose diet treatment in mice induces fundamental disturbance of cardiomyocyte Ca2+ handling and myofilament responsiveness.

Mellor KM, Wendt IR, Ritchie RH, Delbridge LM.

Am J Physiol Heart Circ Physiol. 2012 Feb 15;302(4):H964-72. doi: 10.1152/ajpheart.00797.2011. Epub 2011 Dec 23.

14.

Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway.

Shi H, Han Q, Xu J, Liu W, Chu T, Zhao L.

Gene. 2016 May 25;583(1):8-14. doi: 10.1016/j.gene.2016.02.039. Epub 2016 Feb 28.

PMID:
26930364
15.

Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation.

Heino TJ, Chagin AS, Takigawa M, Sävendahl L.

Bone. 2008 Apr;42(4):702-9. doi: 10.1016/j.bone.2008.01.001. Epub 2008 Jan 16.

PMID:
18276203
16.

The susceptive alendronate-treatment timing and dosage for osteogenesis enhancement in human bone marrow-derived stem cells.

Chang CH, Wang CZ, Chang JK, Hsu CY, Ho ML.

PLoS One. 2014 Aug 26;9(8):e105705. doi: 10.1371/journal.pone.0105705. eCollection 2014.

17.

Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.

Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.

Calcif Tissue Int. 2008 Mar;82(3):191-201. doi: 10.1007/s00223-008-9104-y. Epub 2008 Feb 8.

PMID:
18259679
18.

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ.

Bone. 2008 May;42(5):848-60. doi: 10.1016/j.bone.2007.12.225. Epub 2008 Jan 26.

PMID:
18325866
19.

Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes.

Lee YK, Ng KM, Lai WH, Chan YC, Lau YM, Lian Q, Tse HF, Siu CW.

Stem Cell Rev. 2011 Nov;7(4):976-86. doi: 10.1007/s12015-011-9273-3.

20.

Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport.

Waggoner JR, Ginsburg KS, Mitton B, Haghighi K, Robbins J, Bers DM, Kranias EG.

Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H698-703. doi: 10.1152/ajpheart.00272.2008. Epub 2008 Dec 26.

Supplemental Content

Support Center